OptimizeRx (OPRX) Enterprise Value (2016 - 2025)
OptimizeRx (OPRX) has disclosed Enterprise Value for 16 consecutive years, with -$23.4 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 74.63% to -$23.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$23.4 million through Dec 2025, down 74.63% year-over-year, with the annual reading at -$23.4 million for FY2025, 74.63% down from the prior year.
- Enterprise Value hit -$23.4 million in Q4 2025 for OptimizeRx, down from -$19.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$13.4 million in Q4 2024 to a low of -$89.0 million in Q1 2022.
- Historically, Enterprise Value has averaged -$50.7 million across 5 years, with a median of -$63.1 million in 2023.
- Biggest five-year swings in Enterprise Value: crashed 705.21% in 2021 and later soared 81.32% in 2023.
- Year by year, Enterprise Value stood at -$84.7 million in 2021, then rose by 12.45% to -$74.1 million in 2022, then skyrocketed by 81.32% to -$13.9 million in 2023, then rose by 3.41% to -$13.4 million in 2024, then tumbled by 74.63% to -$23.4 million in 2025.
- Business Quant data shows Enterprise Value for OPRX at -$23.4 million in Q4 2025, -$19.5 million in Q3 2025, and -$16.6 million in Q2 2025.